Related Experiment Videos

Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic

Begoña López1, Arantxa González, Ramón Querejeta

  • 1Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain.

Journal of Hypertension
|January 22, 2009
PubMed

Insights

Plasma cardiotrophin-1 increases with heart failure progression in hypertensive patients. This cytokine shows promise as a biomarker for diagnosing stage C heart failure, potentially improving upon NT-proBNP.

Area of Science:

  • Cardiology
  • Biomarkers
  • Hypertension Research

Background:

  • Cardiotrophin-1 (CT-1) is a cytokine implicated in cardiomyocyte hypertrophy and dysfunction.
  • Elevated CT-1 levels are observed in hypertensive individuals.
  • The role of CT-1 in the progression of heart failure (HF) within hypertensive populations requires further elucidation.

Purpose of the Study:

  • To investigate the association between plasma cardiotrophin-1 and heart failure stages in hypertensive patients.
  • To assess the utility of cardiotrophin-1 as a biomarker for diagnosing stage C heart failure.
  • To compare the diagnostic performance of cardiotrophin-1 with NT-proBNP in this patient group.

Main Methods:

  • Plasma cardiotrophin-1 levels were quantified using enzyme-linked immunosorbent assay (ELISA).
  • Patients were categorized into three groups: Stage A (no cardiac abnormalities), Stage B (left ventricular hypertrophy), and Stage C (left ventricular hypertrophy with clinical HF manifestations).
  • Correlation analyses and receiver operating characteristic (ROC) curve analyses were performed.

Main Results:

  • Plasma cardiotrophin-1 levels demonstrated a significant progressive increase across heart failure stages (P < 0.001).
  • CT-1 showed a direct correlation with left ventricular mass index (r = 0.416, P < 0.001) and an inverse correlation with ejection fraction (r = 0.263, P < 0.01).
  • Cardiotrophin-1 exhibited higher sensitivity (80%) than NT-proBNP (72%) in diagnosing stage C heart failure, particularly in patients with NT-proBNP below the conventional cutoff.

Conclusions:

  • Plasma cardiotrophin-1 is significantly associated with the progression of heart failure in hypertensive patients.
  • Cardiotrophin-1 measurement offers valuable supplementary information for diagnosing stage C heart failure, complementing NT-proBNP assessments.
  • CT-1 may serve as an important biomarker for identifying and managing heart failure in hypertensive individuals.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...